Latest Articles

  • Executive Q&A - A Strategic Acquisition: Insights and Ideas

    An interview with Brian Morrissey, General Manager of Gaelic Laboratories, which has acquired Athlone Laboratories in a strategic deal that typifies the current pharma M&A landscape and puts all of Ireland’s Beta-Lactam manufacturing capacity under one ownership umbrella. read more

  • Limitations of Existing Life Science Software - and the Opportunity to Evolve

    ELNs, LIMS and SDMS systems aren’t going away anytime soon. They provide a foundation for doing reliable, collaborative, and impactful science. The key here is that by embracing and adopting new technologies, scientific organizations can protect their existing investments while unlocking new levels of efficiency, collaboration, and discovery - at their own pace and on their own terms. read more

  • The Dog Days of Summer

    As I write this in the middle of August, during an oppressively humid heat wave, the term “the dog days of summer” comes to mind. If you have never heard that term, it refers to the hottest, most stifling period of summer. Quite apropos, as we are currently experiencing a heat wave. But where did the term come from? read more

  • A Critical Inflexion Point: The Indisputable Case for Next-Gen Pharmacovigilance

    Adverse event case processing is an enormous cost center and compliance issue for life sciences. As revenues stagnate for many pharma companies and profits come under new pressures, the expectation to improve its operational efficiency is substantial. But that cannot be at the expense of quality, or patient safety – the very purpose of pharmacovigilance. Organizations and their PV service providers have no choice but to take a smarter approach, underpinned by artificial intelligence and advanced automation. The cost and risk management benefits are clear, while the wider gains will include a more proactive PV operation, says Qinecsa’s John Cogan. read more